Abstract: In an example embodiment, a solution is provided that introduces a dynamic user interface that automatically identifies payment methods available for a transaction. The dynamic user interface also may optionally present the available payment methods in an ordering, as determined by a machine learning model. More particularly, a payment processing system may determine a payment intents object, with all available payment methods for a transaction and optionally an ordering for those payment methods.

Abstract: An augmented reality system and method for mobile device discovery with indoor and outdoor navigation includes a user device with a processor, memory, a touchscreen user interface and a wireless data interface. The processor generates a map display on the touchscreen including indicia illustrating a position of each of a plurality of MFPs on an associated premises. The processor receives a user selection of an indicia via the touchscreen and displays data corresponding to a status of a selected MFP associated with the user selected indicia. The processor receives a second user selection associated with the user selected indicia via the touchscreen and displays navigation data corresponding to navigation to the selected MFP.

Abstract: The present disclosure relates to thiol-acrylate photopolymerizable resin compositions. The resin compositions may be used for additive manufacturing. One embodiment of the invention includes a photopolymerizable resin for additive manufacturing in an oxygen environment, the resin comprising: a crosslinking component; at least one monomer and/or oligomer and a chain transfer agent comprising at least one of a thiol, a secondary alcohol, and/or a tertiary amine, wherein the resin may be configured to react by exposure to light to form a cured material.

Abstract: The present disclosure relates to thiol-acrylate photopolymerizable resin compositions. The resin compositions may be used for additive manufacturing. One embodiment of the invention includes a photopolymerizable resin for additive manufacturing in an oxygen environment, the resin comprising: a crosslinking component; at least one monomer and/or oligomer; and a chain transfer agent comprising at least one of a thiol, a secondary alcohol, and/or a tertiary amine, wherein the resin may be configured to react by exposure to light to form a cured material.

Abstract: The present disclosure relates to thiol-acrylate photopolymerizable resin compositions. The resin compositions may be used for additive manufacturing. One embodiments of the invention includes a photopolymerizable resin for additive manufacturing in an oxygen environment, the resin comprising: a crosslinking component; at least one monomer and/or oligomer; and a chain transfer agent comprising at least one of a thiol, a secondary alcohol, and/or a tertiary amine, wherein the resin may be configured to react by exposure to light to form a cured material.

Abstract: The present disclosure relates to thiol-acrylate photopolymerizable resin compositions. The resin compositions may be used for additive manufacturing. One embodiment of the invention includes a photopolymerizable resin for additive manufacturing in an oxygen environment, the resin comprising: a crosslinking component; at least one monomer and/or oligomer; and a chain transfer agent comprising at least one of a thiol, a secondary alcohol, and/or a tertiary amine, wherein the resin may be configured to react by exposure to light to form a cured material.

Abstract: A free-flowing solid formulations of drugs or pharmaceutical agents which have poor aqueous solubility are obtained by admixing a liquid or gel composition that includes 1 to 30 percent by weight of the drug, 5 to 60 percent by weight of a surfactant, 10 to 40 percent by weight of water; 1 to 20 percent by weight of unsaturated fatty acid ester, 0 to 50 percent by weight water miscible pharmaceutically acceptable polyol and 1 to 10 percent by weight of phospholipid with a pharmaceutically acceptable suitable solid carrier and thereafter drying the admixture. The free-flowing powder is suitable for being formed into tablets or capsules. The drug or pharmaceutical agent is solubilized in the formulation and has significantly improved bio-availability when compared to the drug tested in its pure form.

Abstract: A free-flowing solid formulations of drugs or pharmaceutical agents which have poor aqueous solubility are obtained by admixing a liquid or gel composition that includes 1 to 30 per cent by weight of the drug, 5 to 60 per cent by weight of a surfactant, 10 to 40 per cent by weight of water; 1 to 20 per cent by weight of unsaturated fatty acid ester, 0 to 50 per cent by weight water miscible pharmaceutically acceptable polyol and 1 to 10 per cent by weight of phospholipid with a pharmaceutically acceptable suitable solid carrier and thereafter drying the admixture. The free-flowing powder is suitable for being formed into tablets or capsules. The drug or pharmaceutical agent is solubilized in the formulation and has significantly improved bio-availability when compared to the drug tested in its pure form.

Abstract: Aqueous liquid or gel formulations of fat soluble vitamins, essential nutrients and other pharmaceutical agents have enhanced concentration of the active components relative to known compositions and therefore have enhanced bioavailability. The aqueous solutions or gels form a free flowing powder when they are absorbed on a suitable pharmaceutically acceptable solid carrier, such as silicon dioxide, maltodextrin, magnesium oxide, aluminum hydroxide, magnesium trisilicate, starch or sugars, or encapsulated by polymers such as gelatin, pectin, chitosan and the like.

Abstract: A free-flowing solid formulations of drugs or pharmaceutical agents which have poor aqueous solubility are obtained by admixing a liquid or gel composition that includes 1 to 30 per cent by weight of the drug, 5 to 60 per cent by weight of a surfactant, 10 to 40 per cent by weight of water; 1 to 20 per cent by weight of unsaturated fatty acid ester, 0 to 50 per cent by weight water miscible pharmaceutically acceptable polyol and 1 to 10 per cent by weight of phospholipid with a pharmaceutically acceptable suitable solid carrier and thereafter drying the admixture. The free-flowing powder is suitable for being formed into tablets or capsules. The drug or pharmaceutical agent is solubilized in the formulation and has significantly improved bio-availability when compared to the drug tested in its pure form.